Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496860 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
A Phase 1 study, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00496860 is a Phase 1 study that has completed, run by Altor BioScience. The registered enrollment target is 26 participants.
The verdict
NCT00496860, a Phase 1 study, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug. The purpose of this study is to evaluate the safety, determine the maximum-tolerated dose (MTD) and characterize the pharmacokinetic profile of ALT-801 in previously treated patients with progressive metastatic malignancies. ALT-801, a recombinant fusion protein with a interleukin-2 (IL-2) component, has a targeting mechanism that recognizes tumor cells with a specific tumor marker.
Interventions
- BIOLOGICAL ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496860
The ClinicalTrials.gov registry entry for NCT00496860 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altor BioScience, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALT-801 is the first listed.
NCT00496860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496860 about?
NCT00496860 is a clinical study titled "Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies". This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug. The purpose of this study is to evaluate the safety, determine the maximum-tolerated dose (MTD) and characterize the pharmacokinetic profile of ALT-801 in previ...
What is the current status of trial NCT00496860?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2007-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00496860?
The interventions under investigation include: ALT-801 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00496860?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.